Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.

Arjun MittraGeraldine H O' Sullivan CoyneJennifer ZlottShivaani KummarRobert MeehanLawrence RubinsteinLamin JuwaraDeborah WilskerJiuping JiBrandon MillerTony NavasKatherine V Ferry-GalowAndrea Regier VothTing-Chia ChangShahanawaz JiwaniRalph E ParchmentJames H DoroshowHelen X Chen

Published in: Cancer chemotherapy and pharmacology (2023)

Intra-tumoral DNA damage response and inhibition of PARP enzymatic activity were confirmed in patients with advanced solid tumors harboring BRCA1/2 mutations after 8 days of talazoparib treatment.

Keyphrases

dna damage response
dna repair
dna damage
hydrogen peroxide
breast cancer risk
nitric oxide
combination therapy
replacement therapy